Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency in-vitro.

(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated Pi‐induced VSMCs. Summarized bar graphs showed EVO significantly decreased mRNA expression of pyroptotic markers (B) NLRP3 and (C) GSDM-D in CER treated Pi&l...

Full description

Saved in:

Bibliographic Details
Main Author:	Razia Rashid Rahil (22772495) (author)
Other Authors:	Salman Shamas (22772498) (author), Nissar Ahmad Wani (13005843) (author), Neha Nanda (2575573) (author), Sheikh Fayaz Ahmad (22772501) (author), Sabry Mohamed Attia (22772504) (author), Abid Hamid (545012) (author), Mohammad Afzal Zargar (18783230) (author), Owais Mohmad Bhat (18783227) (author)
Published:	2025
Subjects:	Microbiology Cell Biology Genetics Molecular Biology Neuroscience Physiology Pharmacology Biotechnology Evolutionary Biology Immunology Developmental Biology Cancer Infectious Diseases Virology alizarin red staining active process driven >&# 946 ;</ calcification via modulation div >< p blocking phenotypic transition evogliptin prevents ceramide evogliptin alleviates vc phenotypic transition vascular calcification severe calcification xlink "> vc ), vascular tissue underlying cause stimulation led pyroptotic markers prior treatment positive impact osteogenic markers mediates inflammation mediated pathway marked upregulation ldh release increased expression diabetic drug data demonstrate control cells cleavage efficiency </ sub
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>

Similar Items